MedPath

Do Oral Steroid Dose Packs Predict How Well Epidural Steroid Injections Will Work?

Terminated
Conditions
Lumbar Spine Disc Herniation
Registration Number
NCT02026726
Lead Sponsor
Dartmouth-Hitchcock Medical Center
Brief Summary

The purpose of this observational study is to show whether a standard oral steroid dose pack can be used as a screening tool to assess the effectiveness of a subsequent epidural steroid injection (ESI). If an oral steroid does not give a patient significant temporary relief of pain from a herniated lumbar disc then an epidural steroid injection will not either. Therefore the risk and expense associated from the interventional pain management procedure for those patients could be avoided and other treatment modalities pursued.

Detailed Description

Not available

Recruitment & Eligibility

Status
TERMINATED
Sex
All
Target Recruitment
10
Inclusion Criteria
  • 18 years and older
  • Diagnosed by participating physicians during the study enrollment period as having intervertebral disk herniation and persistent symptoms with or without some nonoperative treatment for at least 4 weeks
  • Radicular pain (below the knee for lower lumbar herniations, into the anterior thigh for upper lumbar herniations)
  • Evidence of nerve-root irritation with a positive nerve-root tension sign (straight leg raise-positive between 30° and 70°) or a corresponding neurologic deficit (asymmetrical depressed reflex, decreased sensation in a dermatomal distribution)
  • Undergone either MRI or CT scan showing disc herniation (protrusion, extrusion, or sequestered fragment) at a level and side corresponding to the clinical symptoms
  • Patients with multiple herniations can be included if only one of the herniations is considered symptomatic
  • Preenrollment nonprocedural care can include: education/counseling, physical therapy, chiropractic therapy, anti-inflammatory medications, opioid analgesics, adjuvant analgesics such as anticonvulsants and antidepressants
Exclusion Criteria
  • Prior lumbar surgery
  • Cauda equina syndrome
  • Vertebral fractures
  • Spine infection or tumor
  • Severe motor deficit
  • Inflammatory spondyloarthropathy
  • Pregnancy
  • Cardiac or pulmonary comorbid conditions contraindicating interventional procedures
  • Diabetes
  • Inability/unwillingness to have spinal injections

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Change in Patient-Reported PainBaseline,1 wk post oral steroid completion, 2 wks post ESI #1, 2 wks post ESI #2, 2 wks post ESI #3, then at 6 wks, 12 wks, 6 mo. & 12 mo. after last transforaminal ESI (TRESI).

The primary endpoint will be a patient-reported pain as measured by a 10 cm visual analog scale (VAS) with 0 being no pain and 10 being the most severe pain imaginable.

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Dartmouth-Hitchcock Medical Center

🇺🇸

Lebanon, New Hampshire, United States

© Copyright 2025. All Rights Reserved by MedPath